Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash

Psoriatic skin lesions associated with anti-tumor necrosis factor (TNF) agents are well-described in the medical literature. However, the etiology and optimal management of this condition remain unclear. Vedolizumab is a novel, gut-specific, anti-integrin agent used for the treatment of inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsch, Ayal, Colman, Ruben J., Lang, Gabriel D., Rubin, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508952/
https://www.ncbi.nlm.nih.gov/pubmed/26203450
http://dx.doi.org/10.14309/crj.2015.70
_version_ 1782382019780542464
author Hirsch, Ayal
Colman, Ruben J.
Lang, Gabriel D.
Rubin, David T.
author_facet Hirsch, Ayal
Colman, Ruben J.
Lang, Gabriel D.
Rubin, David T.
author_sort Hirsch, Ayal
collection PubMed
description Psoriatic skin lesions associated with anti-tumor necrosis factor (TNF) agents are well-described in the medical literature. However, the etiology and optimal management of this condition remain unclear. Vedolizumab is a novel, gut-specific, anti-integrin agent used for the treatment of inflammatory bowel disease (IBD). We report a case of infliximab-associated psoriasiform lesions in an ulcerative colitis patient. Transition to vedolizumab resulted in resolution of the cutaneous lesions without recurrence and remission of his ulcerative colitis.
format Online
Article
Text
id pubmed-4508952
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American College of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-45089522015-07-22 Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash Hirsch, Ayal Colman, Ruben J. Lang, Gabriel D. Rubin, David T. ACG Case Rep J Case Report Psoriatic skin lesions associated with anti-tumor necrosis factor (TNF) agents are well-described in the medical literature. However, the etiology and optimal management of this condition remain unclear. Vedolizumab is a novel, gut-specific, anti-integrin agent used for the treatment of inflammatory bowel disease (IBD). We report a case of infliximab-associated psoriasiform lesions in an ulcerative colitis patient. Transition to vedolizumab resulted in resolution of the cutaneous lesions without recurrence and remission of his ulcerative colitis. American College of Gastroenterology 2015-07-09 /pmc/articles/PMC4508952/ /pubmed/26203450 http://dx.doi.org/10.14309/crj.2015.70 Text en Copyright © Hirsch et al. This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Case Report
Hirsch, Ayal
Colman, Ruben J.
Lang, Gabriel D.
Rubin, David T.
Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
title Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
title_full Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
title_fullStr Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
title_full_unstemmed Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
title_short Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
title_sort successful treatment of ulcerative colitis with vedolizumab in a patient with an infliximab-associated psoriasiform rash
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508952/
https://www.ncbi.nlm.nih.gov/pubmed/26203450
http://dx.doi.org/10.14309/crj.2015.70
work_keys_str_mv AT hirschayal successfultreatmentofulcerativecolitiswithvedolizumabinapatientwithaninfliximabassociatedpsoriasiformrash
AT colmanrubenj successfultreatmentofulcerativecolitiswithvedolizumabinapatientwithaninfliximabassociatedpsoriasiformrash
AT langgabrield successfultreatmentofulcerativecolitiswithvedolizumabinapatientwithaninfliximabassociatedpsoriasiformrash
AT rubindavidt successfultreatmentofulcerativecolitiswithvedolizumabinapatientwithaninfliximabassociatedpsoriasiformrash

Ejemplares similares